The initiative will explore pathways for conducting future clinical studies in the United States.

Potential inclusion of US sites in upcoming Phase II trials

The collaboration focuses on advancing Neogap’s novel adoptive T-cell therapy, pTTL (personalised Tumour Trained Lymphocytes), which uses tumour-draining lymph nodes as a source of tumour-reactive T cells and applies a multi-neoantigen targeting approach. The aim is to make personalised immunotherapy for solid cancers more efficient and broadly accessible.

Combining Neogap’s clinical and technological expertise with Weill Cornell Medicine’s experience in TIL therapy, lung cancer surgery, and translational immuno-oncology – and specifically drawing on Dr Jonathan Villena-Vargas’s insights into tumour-draining lymph nodes – the project will assess how Neogap’s personalised cell therapy may be integrated into clinical practice and prepare for the potential inclusion of US sites in upcoming Phase II trials.

“Collaborating with Weill Cornell Medicine is an important step in our international development. It allows us to connect Neogap’s clinical progress in Sweden with leading US expertise in cell therapy and translational oncology. This project not only prepares us for future clinical trials in the United States but also reinforces the global relevance of our novel personalized immunotherapy,” says Samuel Svensson, CEO of Neogap Therapeutics.

Sweden–US collaboration

This collaboration marks a significant step in Neogap’s strategy to expand its clinical and regulatory footprint internationally and contributes to aligning Swedish and US approaches to regulatory, data, and material transfer in personalized immunotherapy. Funded by Vinnova under its programme for international research and innovation collaboration, the project supports the expansion of Neogap’s T-cell therapy through Sweden–US collaboration.